NPPB and hydrops fetalis: The open study PROVE-HF (54) included patients with de novo HF, who had not been previously treated with ACEI/ARB II, with low levels of NT-proBNP, and with submaximal doses of sacubitril/valsartan, at a mean of 50 months (more than 4 years) from the diagnosis of HF.